SUTENT (sunitinib malate) is indicated for the treatment of advanced renal cell carcinoma (RCC) and for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.

View: SUTENT | Prescribing information

TORISEL (temsirolimus) is indicated for the treatment of advanced renal cell carcinoma.

View: TORISEL | Prescribing information

AROMASIN (exemestane tablets) is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy.

AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

View: AROMASIN | Prescribing information

CAMPTOSAR (irinotecan hydrochloride injection) is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

View: CAMPTOSAR | Prescribing information